Skip to main content
SpringerLink
Log in

Diagnostik

  • Chapter
Management des Ovarialkarzinoms

Part of the book series: Onkologie aktuell ((ONKAKTUELL))

  • 1346 Accesses

Auszug

Ziel jeglicher Diagnostik muss sein, Tumoren im Unterbauch zu identifizieren, sie den verschiedenen möglichen Ursprungsorganen zuzuordnen und zwischen benigne und maligne zu differenzieren. Ausgangspunkt jeder Untersuchung ist eine sorgfältige klinische Anamnese, die Beachtung auch unspezifischer Symptome und eine ausführliche klinische Untersuchung auf der Basis der bimanuellen Tastuntersuchung des kleinen Beckens. Diese klinische Untersuchung wird ergänzt durch die bildgebenden Verfahren, insbesondere den transvaginalen und den transabdominalen Ultraschall sowie die radiologische Diagnostik mittels Computertomogramm und MRT. Wichtig zu wissen ist, dass eine endgültige Dignitätsbeurteilung bisher mit keinem der bildgebenden Verfahren möglich ist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • DiSaia PJ, Creasman WT; Clinical gynecologic oncology, 7th ed., Mosby & Co., St. Louis, MO, 2007

    Google Scholar 

  • Hugh R.K. Barber, Edward A. Graber, Tae hae Kwon, Ovarian Cancer, CA Cancer J Clin 1974; 24:340

    Google Scholar 

  • Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. Koordination: Prof. Dr. Barbara Schmalfeldt, München, Prof. Dr. Jacobus Pfisterer, Kiel. Zuckschwerdt, München 2007

    Google Scholar 

  • Manual Maligne Ovarialtumoren; Tumorzentrum München, Zuckschwerdt, München 2007

    Google Scholar 

Literatur

  • Alcazar JL, Jurado M (1999) Prospective evaluation of logistic model based on sonographic morphologic and color Doppler findings developed to predict adnexal malignancy. J Ultrasound Med 18: 837–842

    PubMed  CAS  Google Scholar 

  • Alcazar JL, Erasti T, Laparte c, Jurato M, Lopez-Garcia G (2001) Assessment of a new logistic model in the preoperativ evaluation of adnexal masses J Ultrasound Med 20:842–848

    Google Scholar 

  • Bailey CL, Ueland FR, Land GL et al. (1998) The malignant potential of small cystic ovarian tumors in women over 50 years of age. Gynecol Oncol 69: 3–7

    Article  PubMed  CAS  Google Scholar 

  • Bundesgeschäftsstelle Qualitätssicherung (2003, 2004, 2005) BQS-Qualitätsreport: Indikation bei Ovarialeingriffen. Verfügbar unter www.bqs-qualitaetsreport.de [5.9.2008]

    Google Scholar 

  • D’Arcy TJ, Jayaram V, Lynch M, Soutter WP, Cosgrove DO, Harvey GL (2004) Ovarian cancer detected non-invasively by contrast-enhanced Doppler ultrasound. Br J Obstet Gynecol 111: 619–622

    Google Scholar 

  • DePriest PD, Shenson D, Fried A et al. (1993) A morphology indexed based on sonographic findings in ovarian cancer. Gynecol Oncol 51: 7–11

    Article  PubMed  CAS  Google Scholar 

  • DGGG, DKG, AGO (2004) Leitlinien, Empfehlungen, Stellungnahmen. 2.2.7 Maligne Ovarialtumoren. AWMF 032/042. Aktualisiert bestätigt März 2004

    Google Scholar 

  • Ekerhovd E, Wienerroith H, Staudach A, Granberg S (2001) Preoperative assessment of unilocular adrenal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol 184: 48–54

    Article  PubMed  CAS  Google Scholar 

  • Emoto M, Fujimitsu R, Iwasaki H, Kawarabayashi T (2003) Case 3. Normal-sized ovarian cancer detected by color Doppler ultrasound using a microbubble contrast agent. J Clinical Oncology 19: 3703–3705

    Article  Google Scholar 

  • Gohagan JK, Prorock PC, Hayes RB, Kramer BS for the PLCO Project Team (2000) The prostate, lung, coloreectal and ovarian (PLCO) cancer screening trial of the National Cancer Institute: History, organization, and status. Controlled Clinical Trials 21: 273S–309S

    Article  PubMed  Google Scholar 

  • Guerriero S, Alcazar JL, Coccia ME et al. (2002) Complex pelvic mass as a target for evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies J Ultrasound Medicine 21: 1105–1111

    Google Scholar 

  • Jacobs IJ, Skates SJ, MacDonald N et al. (1999) Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 354 9160) 1207–210

    Article  Google Scholar 

  • Kindermann G, Maassen V, Kuhn W (1996) Laparoscopic management of ovarian tumors subsequently diagnosed as malignant. J of Pelvic Surgery 2: 245–251

    Google Scholar 

  • Kupesic S, Kurjak A (2000) Contrast-enhanced, three dimensional power Doppler Sonography. Obstet Gynecol 96: 452–458

    Article  PubMed  CAS  Google Scholar 

  • Kurjak SA, Kupesic S, Sparac V, Prka M, Bekavac I (2003) The detection of stage I ovarian cancer by three-dimensional sonography and power Doppler. Gynecol Oncol 90: 258–264

    Article  PubMed  Google Scholar 

  • Marret H, Ecohard R, Giraudeau B, Golfier F, Raudrant D, Lansac J (2002) Color Doppler energy prediction of malignancy in adnexal masses using logistic regression models., Ultrasound Obstet Gynecol 20: 597–604

    Article  PubMed  CAS  Google Scholar 

  • Merz E, Weber G, Bahlmann F, Kießlich R (1998) A new sonomorphologic scoring system (Mainz Score) the assessment of ovarian tumors using transvaginal ultrasonography. Part I Premenopause. Ultraschall Med 19: 99–107

    Article  PubMed  CAS  Google Scholar 

  • Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, Nagell JR van (2003) Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 102: 594–599

    Article  PubMed  Google Scholar 

  • Nagell JR van, De Priest PD, Reedy MB et al. (2000) The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 77: 350–356

    Article  PubMed  Google Scholar 

  • Orden MR, Jurvelin JS, Kirkinen PP (2002) Kinetics of a US contrast agent in benign and malignant adnexal tumors. Radiology 226: 405–410

    Article  Google Scholar 

  • Osmers R, Osmers M, Maydell B von, Wagner B, Kuhn W (1996) Preoperativ evaluation of ovarian tumors in premenopause by transvaginalsonography. Am J Obstet Gynecol 175: 428–434

    Article  PubMed  CAS  Google Scholar 

  • Osmers R, Osmers M, Maydell B von, Wagner B, Kuhn W (1998) Evaluation of ovarian tumors in postmenopausal women by transvaginal sonography. Eur J Obstet Gynecol Reprod Biol 77: 81–8

    Article  PubMed  CAS  Google Scholar 

  • Pfleiderer A (2002) Gutartige Ovarialtumoren und Borderline-Tumoren. Gynäkologe 35: 689–704

    Google Scholar 

  • Prömpeler HJ, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A (1994) Quantitative flow measurements for dassification of ovarian tumors by transvaginal color Doppler sonography in postmenopausal patients. Ultrasound Obstet Gynecol 4: 406–413

    Article  PubMed  Google Scholar 

  • Prömpeler HJ, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A (1996) Kombinierte Beurteilung von Ovarialtumoren mit transvaginaler B-Bild-und Farbdoppler-Sonographie. Geburtsh Frauenheilkd 56: 345–350

    Article  Google Scholar 

  • Prömpeler HJ, Karck U, Madjar H, Lattermann U, Breckwoldt M (1997a) Sonograhische Diagnostik von Dermoidzysten (Sonomorphologie und Vaskularisation). Geburtsh Frauenheilkd 57: 463–467

    Article  Google Scholar 

  • Prömpeler HJ, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A (1997b) Diagnostic formula for the differentiation of adnexal tumors by transvaginal sonography. Obstet Gynecol 89: 428–433

    Article  PubMed  Google Scholar 

  • Prömpeler HJ, Randelzhofer B, Sauerbrei W, Madjar H (2000) Überprüfung der Diagnose-Formel für Ovarialtumoren. Ultraschall in der Medizin 21: 563

    Google Scholar 

  • Prömpeler HJ, Watermann D, Emmerich D, Denschlag D, Pauer U, Sauerbrei W (2002) Vaskularisation von Ovarialtumoren. Eine multivariate Analyse. Ultraschall Med 24: 2

    Google Scholar 

  • Sassone M, Timor-Tritsch IE, Artner A, Westhoff C, Warren WB (1991) Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 78: 70–76

    PubMed  CAS  Google Scholar 

  • Schelling M, Braun M, Kuhn W et al. (2000) Combined transvaginal D-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol 77: 78–86

    Article  PubMed  CAS  Google Scholar 

  • Tekay A, Jouppila P (1996) Controversies in assessment of ovarian tumors with transvaginal color Doppler ultrasound. Acta Obstet Gynecol Scand 75: 316–29

    Article  PubMed  CAS  Google Scholar 

  • Timmermann D (2004) The use of mathematical models to evaluate pelvic masses; can thea beat an expert operator? Best Practice & Research Clinical Obstetrics and Gynecology 18: 91–104

    Article  Google Scholar 

  • Timmermann D, Verrelst H, Bourne TH, DeMoor B, Collins WP, Vergote I, Vandewalle J (1999) Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. Ultrasound Obstet Gynecol 13: 17–25

    Article  Google Scholar 

  • Timmermann D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I (2000) Terms, definition and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound Obstet Gynecol 16: 500–5

    Article  Google Scholar 

  • Timmermann D, Testa AC, Bourne T et al. (2005) Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the IOTA Group. JCO 23: 8794–8801

    Article  Google Scholar 

  • Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, Nagell JR van (2003) Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol 91: 46–50

    Article  PubMed  CAS  Google Scholar 

  • Valentin L (1999a) High-quality gynecological ultrasound can be highly beneficial, but poor-quality gynecological ultrasound can do harm Ultrasound Obstet Gynecol 13: 1–7

    Article  PubMed  CAS  Google Scholar 

  • Valentin L (1999b) Pattern Recognition of pelcic masses by grea-scale ultrasound imaging: the contribution of Doppler ultrasound. Obstet Gynecol 14: 338–347

    CAS  Google Scholar 

  • Valentin L (2000) Comparison of Lerner score, Doppler ultrasound examination, and their combination for discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol 15: 143–147

    Article  PubMed  CAS  Google Scholar 

  • Valentin L, Sladkevicius P, Marsal K (1994) Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors. Obstet Gynecol 83: 425–433

    PubMed  CAS  Google Scholar 

  • Valentin L, Hagen B, Tingulstad S, Eik-Nes S (2001) Comparison of »pattern recognition« and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol 18: 357–365

    Article  PubMed  CAS  Google Scholar 

  • Valentin L, Ameye L, Jurkovic D, Metzger U, Lecuru F, Van Huffel S, Timmerman D (2006) Which extrauterine pelvic masses are difficult to correctly classify as benign or malignant on the basis of ultrasound findings and is there a way of making a correct diagnosis? Ultrasound Obstet Gynecol 27: 438

    Article  PubMed  CAS  Google Scholar 

  • Weber G, Merz E, Bahlmann F, Leber AM (1999) A new sonomorphologic scoring system (Mainz Score) the assessment of ovarian tumors using transvaginal ultrasonography. Part II Postmenopause. Ultraschall Med 20: 2–8

    Article  PubMed  CAS  Google Scholar 

Literatur

  • American Cancer Society (1998) Cancer facts and figures: 1998, American Cancer Society, p 13. Verfügbar unter www.cancer.org [29.08.2008]

    Google Scholar 

  • Imaoka I, Wada A, Kaji Y et al. (2006) Developing an MR imaging strategy fpr diagnosis of ovarian masses. Radiographics 26(5): 1431–1448

    Article  PubMed  Google Scholar 

  • Hricak H, Chen M, Coakley FV et al. (2000) Complex adnexal masses: detection and characterization with MR imaging—multivariate analysis. Radiology 214: 39–46

    PubMed  CAS  Google Scholar 

  • Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST (2002) CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics 22: 1305–1325

    Article  PubMed  Google Scholar 

  • Kim SH, Kim WH, Park KJ, Lee JK, Kim SJ (1996) CT and MR findings of Krukenberg tumors: comparison with primary ovarian tumors. J Comput Assist Tomogr 20: 393–398

    Article  PubMed  CAS  Google Scholar 

  • Kinkel K, Ariche M, Tardivon AA et al. (1997) Differentiation between recurrent tumor and benign-conditions after treatment of gynecolic pelvic carcinoma: value of dynamic contrast-subtraction MR imaging. Radiology 204: 55–63

    PubMed  CAS  Google Scholar 

  • Kurtz AB, Tsimikas JV, Tempany CM et al. (1999) Diagnosis and staging of ovarian cancer: comparative values of Dopler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis—report of the Radiology Diagnostic Oncology Group. Radiology 212: 19–27

    PubMed  CAS  Google Scholar 

  • Low RN, Saleh F, Song SY et al. (1999) Treated ovarian cancer: comparison of MR imaging with serum CA-125 level and physical examination-a longitudinal study. Radiology 211: 519–528

    PubMed  CAS  Google Scholar 

  • Meyer JI, Kennedy AW, Friedman R, Ayoub A, Zepp RC (1995) Ovarian carcinoma: value of CT in predicting success of debulking surgery. Am J Roentgenol 165: 875–878

    CAS  Google Scholar 

  • Nitzsche EU, Hoh CK, Dalbohm M, Glaspy A, Phelps ME, Moser EA (1993) Ganzkörper-Positronen-Emissions-Tomographie beim Mammakarzinom. Fortschr Röntgenstr 158: 293–298

    Article  CAS  Google Scholar 

  • Outwater EK, Huang AB, Dunton CJ, Talerman A, Capuzzi DM (1997) Papillary projection in ovarian neoplasms: appearance in MRI. J Magn Reson Imaging 7: 689–695

    Article  PubMed  CAS  Google Scholar 

  • Outwater EK, Siegelman ES, Kim B, Chiowanich P, Blasbalg R, Kilger A (1998) Ovarian Brenner tumors: MR imaging characteristics. Magn Reson Imaging 16: 1147–1153

    Article  PubMed  CAS  Google Scholar 

  • Rieber A, Nüssle K, Stöhr I et al. (2001) Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. Am J Roentgenol 177: 123–129

    CAS  Google Scholar 

  • Risum S, Hogdall C, Loft A et al. (2007) The diagnostic value of PET/CT for primary cancer—A prospective study. Gynecol Oncol 105: 145–149

    Article  PubMed  Google Scholar 

  • Scully RE, Young RH, Clement PB (1996) Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. Atlas of Tumor Pathology, Armed Forces Institute of Pathology, Washington.

    Google Scholar 

  • Tanaka YO, Kurosaki Y, Nishida M et al. (1994) Ovarian dysgerminoma: MR and CT appearance. J Comput Assist Tomogr 18: 443–448

    Article  PubMed  CAS  Google Scholar 

  • Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ (2000) Staging of advanced ovarian cancer: comparison of imaging modalities—report of the Radiology Diagnostic Oncology Group. Radiology 215: 761–767

    PubMed  CAS  Google Scholar 

  • Thrall MM, Deloia JA, Gallion H, Avril N (2007) Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol 105: 17–22

    Article  PubMed  Google Scholar 

  • Togashi K, Nishimura K, Itoh K et al. (1987) Ovarian cystic teratomas: MR imaging. Radiology 162: 669–673

    PubMed  CAS  Google Scholar 

  • Togashi K (2003) Ovarian cancer: the clinical role of US, CT, and MRI. Eur Radiology 13: L87–L104

    Article  Google Scholar 

  • Troiano RN, Lazzarini KM, Scout LM, Lange RC, Flynn SD, Mc Carthy S (1997) Fibroma and fibrothecoma of the ovary: MR imaging findings. Radiology 204: 795–798

    PubMed  CAS  Google Scholar 

  • Young RH, Scully RE (1994) Metastatic tumors of the ovary. In: Kurman RJ (ed) Blaustein’s pathology of the female genital tract. Springer, Berlin Heidelberg New York, pp 939–974

    Google Scholar 

Literatur

  • An H. J., Kim D. S., Park Y. K. et al., Comparative proteomics of ovarian epithelial tumors, J Proteome Res 5 (2006) 1082–1090 [www. cancer.gov/cancertopics/pdq/screening/overview]

    Article  PubMed  CAS  Google Scholar 

  • Baekelandt M., Khouja H., Kristensen G. B., Nesland J., Holm R., The potential prognostic and predicitive significance of cell cycle-related proteins Ki-67, p16, p14 and p57 in advanced ovarian cancer. J Clin Oncol 22 (2004), ASCO Annual Meeting Proceedings 2004, Abstract 5042

    Google Scholar 

  • Barnholtz-Sloan J. S., Tainsky M. A., Abrams J. et al., Ethnic differences in survival among women with ovarian carcinoma. Cancer 94 (2002) 1886–1893

    Article  PubMed  Google Scholar 

  • Brockbank E. C., Ind T. E., Barton D. P. et al., Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer, Int J Gynecol Cancer 14 (2004) 42–50

    Article  PubMed  CAS  Google Scholar 

  • Brose M. S., Rebbeck T. R., Calzone K. A. et al., Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94 (2002) 1365–1372

    PubMed  CAS  Google Scholar 

  • Brun J. L., Feyler A., Chene G., Saurel J., Brun G., Hocke C., Long-term results and prognostic factors in patients with epithelial ovarian cancer, Gynecol Oncol 78 (2000) 21–27

    Article  PubMed  CAS  Google Scholar 

  • Brustmann H., Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomer ase II alpha and prognosis, Gynecol Oncol 95 (2004) 16–22

    Article  PubMed  CAS  Google Scholar 

  • Check E., News feature: Running before we can walk?, Nature 429 (2004) 496–497

    Article  PubMed  CAS  Google Scholar 

  • Chi D. S., Venkatraman E. S., Masson V., Hoskins W. J., The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma, Gynecol Oncol 77 (2000) 227–231

    Article  PubMed  CAS  Google Scholar 

  • Codegoni A. M., Broggini M., Pitelli M. R. et al., Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol 65 (1997) 130–137

    Article  PubMed  CAS  Google Scholar 

  • Coleman R., Herzog T., Hosford S. et al., An ex vivo chemoresponse assay predicts carboplatin-induced progression-free interval in ovarian cancer. J Clin Oncol 22, ASCO Annual Meeting Proceedings, (2004), Abstract 5134

    Google Scholar 

  • Colitti C. V., Rodabaugh K. J., Welch W. R., Berkowitz R. S., Mok S. C., A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas, Oncogene 16 (1998) 555–559

    Article  PubMed  CAS  Google Scholar 

  • Conrads T. P., Veenstra T. D., The utility of proteomic patterns for the diagnosis of cancer, Curr Drug Targets Immune Endocr Metabol Disord 4 (2004) 41–50

    Article  PubMed  CAS  Google Scholar 

  • Conrads T. P., Zhou M., Petricoin E. F. 3rd, Liotta L., Veenstra T. D., Cancer diagnosis using proteomic patterns, Expert Rev Mol Diagn 3 (2003) 411–420

    Article  PubMed  CAS  Google Scholar 

  • Conrads T. P., Fusaro V. A., Ross S. et al., High-resolution serum proteomic features for ovarian cancer detection, Endocr Relat Cancer 11 (2004a) 163–178

    Article  PubMed  CAS  Google Scholar 

  • Conrads T. P., Hood B. L., Issaq H. J., Veenstra T. D., Proteomic patterns as a diagnostic tool for early-stage cancer: a review of its progress to a clinically relevant tool, Mol Diagn 8 (2004b) 77–85

    Article  PubMed  Google Scholar 

  • Daly M. B., R. F. Ozols, The search for predictive patterns in ovarian cancer: proteomics meets bioinformatics, Cancer Cell 1 (2002) 111–112

    Article  PubMed  CAS  Google Scholar 

  • Diamandis E. P., Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations, Mol Cell Proteomics 3 (2004a) 367–378

    Article  PubMed  CAS  Google Scholar 

  • Diamandis E. P., OvaCheck: doubts voiced soon after publication, Nature 430 (2004b) 611

    Article  PubMed  CAS  Google Scholar 

  • Dressman H. K., Berchuck A., Chan G. et al., An integrated genommic based approach to individualized treatment of patients with advanced-stage ovarian cancer, J Clin Oncol 25 (2007) 517–525

    Article  PubMed  CAS  Google Scholar 

  • Foti E., Ferrandina G., Martucci R. et al., IL-6, M-CSF and IAP cytokines in ovarian cancer: simultaneous assessment of serum levels, Oncology 57 (1999) 211–215

    Article  PubMed  CAS  Google Scholar 

  • Gallion H., Christopherson W., Coleman R. T. et al., Ex vivo chemoresponse assay of ovarian cancers predicts clinical outcome, J Clin Oncol 22, ASCO Annual Meeting Proceedings (2004) Abstract 5074

    Google Scholar 

  • Gifford G., Paul J., Vasey P. A. et al., The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients, Clin Cancer Res 10 (2004) 4420–4426

    Article  PubMed  CAS  Google Scholar 

  • Haaften-Day C. van, Shen Y., Xu F. et al., OVX1 macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal, Cancer 92 (2001) 2837–2844

    Article  PubMed  Google Scholar 

  • Hellstrom I., Raycraft J., Hayden-Ledbetter M. et al., The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res 63 (2003) 3695–3700

    PubMed  Google Scholar 

  • Ismail R. S., Baldwin R. L., Fang J. et al., Differential gene expression between normal and tumor-derived ovarian epithelial cells, Cancer Res 60 (2000) 6744–6749

    PubMed  CAS  Google Scholar 

  • Jones M. B., Krutzsch H., Shu H. et al., Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer, Proteomics 2 (2002) 76–84

    Article  PubMed  CAS  Google Scholar 

  • Kauff N. D., Satagopan J. M., Robson M. E. et al., Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation, N Engl J Med 346 (2002) 1609–1615

    Article  PubMed  Google Scholar 

  • Kim J. H., Skates S. J., Uede T. et al., Osteopontin as a potential diagnostic biomarker for ovarian cancer, Jama 287 (2002) 1671–1679

    Article  PubMed  CAS  Google Scholar 

  • Kornblith P., Wells A., Gabrin M. J. et al., In vitro responses of ovarian cancers to platinums and taxanes, Anticancer Res 23 (2003) 543–548

    PubMed  CAS  Google Scholar 

  • Kornblith P., Ochs R. L., Wells A. et al., Differential in vitro effects of chemotherapeutic agents on primary cultures of human ovarian carcinoma, Int J Gynecol Cancer 14 (2004) 607–615

    Article  PubMed  CAS  Google Scholar 

  • Lancaster J. M., Wooster R., Mangion J. et al., BRCA2 mutations in primary breast and ovarian cancers, Nat Genet 13 (1996) 238–240

    Article  PubMed  CAS  Google Scholar 

  • Levine D. A., Bonome T., Ohlshen A. B. et al., Gene expression profiling of advanced ovarian cancers to predict the outcome of primary surgical cytoreduction, J Clin Oncol 22, ASCO Annual Meeting Proceedings (2004) Abstract 5000

    Google Scholar 

  • Li A. J., Madden A. C., Cass I., Leuchter R. S., Lagasse L. D., B. Y. Karlan. The prognostic significance of thrombocytosis in epithelial ovarian carcinoma, Gynecol Oncol 92 (2004) 211–214

    Article  PubMed  Google Scholar 

  • Lin Y. W., Lin C. Y., Lai H. C. et al., Plasma proteomic pattern as biomarkers for ovarian cancer, Int J Gynecol Cancer 16, Suppl 1 (2006) 139–146

    Article  PubMed  Google Scholar 

  • Massey A., Offman J., Macpherson P., P. Karran, DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells, DNA Repair (Amst) 2 (2003) 73–89

    Article  CAS  Google Scholar 

  • Matei D., Graeber T. G., Baldwin R. L. et al., Gene expression in epithelial ovarian carcinoma, Oncogene 21 (2002) 6289–6298

    Article  PubMed  CAS  Google Scholar 

  • Miki Y., Swensen J., Shattuck-Eidens D. et al., A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science 266 (1994) 66–71

    Article  PubMed  CAS  Google Scholar 

  • Mok S. C., Chao J., Skates S. et al., Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology, J Natl Cancer Inst 93 (2001) 1458–1464

    Article  PubMed  CAS  Google Scholar 

  • Mougeot J. L., Bahrani-Mostafavi Z., Vachris J. C. et al., Gene expression profiling of ovarian tissues for determination of molecular pathways reflective of tumorigenesis, J Mol Biol 358 (2006) 310–329

    Article  PubMed  CAS  Google Scholar 

  • Ng T. Y., Ngan H. Y., Cheng D. K., L. C. Wong, Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples, Gynecol Oncol 76 (2000) 405–408

    Article  PubMed  CAS  Google Scholar 

  • Nishizuka S., Chen S. T., Gwadry F. G. et al., Diagnostic markers that distinguish colon and ovarian adenocarcinomas identification by genomic, proteomic and tissue array profiling. Cancer Res 63 (2003) 5243–5250

    PubMed  CAS  Google Scholar 

  • Obeidat B., Latimer J., Can optimal primary cytoreduction be predicted in advanced-stage epithelial ovarian cancer?, Obstet Gynecol Surv 59 (2004) 709–711

    Article  Google Scholar 

  • Oh J. H., Gao J., Nandi A., P. Gurnani, L. Knowles, Schorge J., Diagnosis of early relapse in ovarian cancer using serum proteomic profiling, Genome Inform 16 (2005) 195–204

    PubMed  CAS  Google Scholar 

  • Ohishi Y., Oda Y., Uchiumi T. et al., ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma, Clin Cancer Res 8 (2002) 3767–3775

    PubMed  CAS  Google Scholar 

  • Olivier R. I., Beurden M. van, Lubsen M. A. et al., Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up, Br J Cancer 90 (2004) 1492–1497

    Article  PubMed  CAS  Google Scholar 

  • Olopade O. I., G. Artioli, Efficacy of risk-reducing salpingo-oophorectomy in women with BRCA-1 and BRCA-2 mutations, Breast J 10, Suppl 1 (2004) S5–9

    Article  PubMed  Google Scholar 

  • Ozols R. F., Optimum chemotherapy for ovarian cancer, Int J Gynecol Cancer 10 (2000a) 33–37

    Article  PubMed  Google Scholar 

  • Ozols R. F., Management of advanced ovarian cancer consensus summary. Advanced Ovarian Cancer Consensus Faculty. Semin Oncol 27 (2000b) 47–49

    PubMed  CAS  Google Scholar 

  • Perez E. A., Pusztai L., M. Van de Vijver, Improving patient care through molecular diagnostics, Semin Oncol 31 (2004) 14–20

    Article  PubMed  CAS  Google Scholar 

  • Petricoin E. F., Ardekani A. M., Hitt B. A. et al., Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572–577

    Article  PubMed  CAS  Google Scholar 

  • Pieretti M., Hopenhayn-Rich C., Khattar N. H. et al., Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival. Cancer Invest 20 (2002) 11–23

    Article  PubMed  Google Scholar 

  • Psyrri D., Bamias A., Yu Z., Markakis S. et al., Molecular predictors for response to carboplatin and paclitaxel (CP) chemotherapy in patients with ovarian cancer, J Clin Oncol 22, ASCO Annual Meeting Proceedings (2004) Abstract 5066

    Google Scholar 

  • Rebbeck T. R., Lynch H. T., Neuhausen S. L. et al., Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations, N Engl J Med 346 (2002) 1616–1622

    Article  PubMed  Google Scholar 

  • Sakamoto M., Kondo A., Kawasaki K. et al., Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray, Hum Cell 14 (2001) 305–315

    PubMed  CAS  Google Scholar 

  • Scartozzi M., De Nictolis M., Galizia E. et al., Loss of hMLH1 expression correlates with improved survival in stage III–IV ovarian cancer patients, Eur J Cancer 39 (2003) 1144–1149

    Article  PubMed  CAS  Google Scholar 

  • Simsek T., Ozbilim G., Gulkesen H., Kaya H., Sargin F., Karaveli S., Drug resistance in epithelial ovarian cancer: P-glycoprotein and glutation S-transferase. Can they play an important role in detecting response to platinum-based chemotherapy as a first-line therapy, Eur J Gynaecol Oncol 22 (2001) 436–438

    PubMed  CAS  Google Scholar 

  • Spentzos D., Levine D. A., Ramoni M. F. et al., A gene expression signature with independent prognostic significance in epithelial ovarian cancer, J Clin Oncol 22 (2004) 4700–4710

    Article  PubMed  Google Scholar 

  • Thompson D., Easton D. F, Cancer incidence in BRCA1 mutation carriers, J Natl Cancer Inst 94 (2002) 1358–1365

    PubMed  CAS  Google Scholar 

  • Wei S. H., Chen C. M., Strathdee G. et al., Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progressionfree survival in patients and identifies candidate epigenetic markers, Clin Cancer Res 8 (2002) 2246–2252

    PubMed  CAS  Google Scholar 

  • Wei S. H., Brown R., Huang T. H., Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response?, Ann N Y Acad Sci 983 (2003) 243–250

    Article  PubMed  CAS  Google Scholar 

  • Welsh J. B., Zarrinkar P. P., Sapinoso L. M. et al., Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer, Proc Natl Acad Sci U S A 98 (2001) 1176–1181

    Article  PubMed  CAS  Google Scholar 

  • Wong K. K., Cheng R. S., Mok S. C., Identification of differentially expressed genes from ovarian cancer cells by MICROMAX cDNA microarray system, Biotechniques 30 (2001) 670–675

    PubMed  CAS  Google Scholar 

  • Xu F. J., Yu Y. H., Daly L. et al., OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures, J Clin Oncol 11 (1993) 1506–1510

    PubMed  CAS  Google Scholar 

Literatur

  • Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMACI gene: a tumor suppressor with lip phosphatase activity. J Nat Cancer Inst 91, 1922–32. 1999

    Article  PubMed  CAS  Google Scholar 

  • Bois A du, Meier W, Luck HJ et al. Chemotherapy versus hormonal treatment in platinum-and paditaxel refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 13(2), 251–57. 2002

    Article  Google Scholar 

  • Buttitta F, Marchetti A, Gaducci A et al. p53 alterations are predictive of chemoresistance and aggresivness in ovarian carcinomas: a molecular and immun-histochemical study. Br J Cancer 75, 230–35. 1997

    PubMed  CAS  Google Scholar 

  • Cheng JQ, Jiang X, Fraser M, Li M, Dan HC, Sun M, Tsang BK. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvment of phosphoinoside-3 kinase/Akt pathway. Drug resist Updat 5, 131–46, 2002

    Article  PubMed  CAS  Google Scholar 

  • Devaraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell death proteases. Nature 388, 300–04. 1997

    Article  Google Scholar 

  • Eltabbakh GH, Awtrey CS. Current treatment for ovarian cancer. Expert Opin Pharmacoth 2, 109–24. 2001

    Article  CAS  Google Scholar 

  • Fortin A, Creagan SP, MacLaurin JG et al. APAFI is a key transcriptional target for p53 in the regulation of neuronal cell death. J Biol Chem 155, 207–16. 2002

    Google Scholar 

  • Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer. The role of apoptotic regulators. Reproductive Biol and Endocrinology 1, 66, 2003a. Verfügbar unter www.rbej.com/content/pdf/1477-7827-1-66.pdf [12.9.2008]

    Article  Google Scholar 

  • Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinat of Xiap/Akt mediated chemoresistance in human ovarian Cancer. Cancer Res 63 (21), 7081–7088. 2003b

    PubMed  CAS  Google Scholar 

  • Gordon, Alan N. et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal Doxorubicin versus Topotecan. Journal of Clinical Oncology 19(14), 3312–22. 2001

    PubMed  CAS  Google Scholar 

  • Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M. Cross-talk between Akt, p53 and MDM-2: possible implications for the regulation of apoptosis. Oncogene 21, 1299–303. 2002

    Article  PubMed  CAS  Google Scholar 

  • Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Letters 420, 25–27. 1997

    Article  PubMed  CAS  Google Scholar 

  • Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62, 1087–92. 2002

    PubMed  CAS  Google Scholar 

  • Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 3, 112–21. 2002

    Article  PubMed  CAS  Google Scholar 

  • Koshiyama M, Fuji H, Kinezaki M, Morita Y, Nanno H, Yoshida M. Immun histochemical expression of topoisomerase llalpha (Topo II alpha) and multidrugresistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indicies of ovarian and endometrial carcinomas. Anticancer Res 21(4B), 2925–32. 2001

    PubMed  CAS  Google Scholar 

  • Li J, Fenq MF, Kim JM et al. Human ovarian cancer and cisplatin resistence: possible role of inhibitor of apoptosis proteins. Endocrinology 142, 370–80. 2001

    Article  PubMed  CAS  Google Scholar 

  • Mano MS, Awada A, Di Leo A et al. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma. Gyn Oncol 92, 887–95. 2004

    Article  CAS  Google Scholar 

  • Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/akt pathway promotes translocation of mdm-2 from cytoplasma to nucleus. Proc Natl Acad Sci USA 98, 11598–603. 2001

    Article  PubMed  CAS  Google Scholar 

  • Meier W, Bois A du, Kuhn W, Pfisterer J, Kimmig R, Olbricht S, Richter B. Topotecan vs. Treosulfan in recurrent ovarian cancer (OC) after initial therapy with platinum and paclitaxel. A prospective randomised phase III study. Proc Am Soc Clin Oncol 22, 450. 2003

    Google Scholar 

  • Nicolantonio F di, Mercer SJ, Knight LA et al. Cancer cell adaption to chemotherapy. BMC Cancer 5, 78. 2005

    Article  PubMed  CAS  Google Scholar 

  • Ogawara Y, Kishishita S, Obata T et al. Akt enhanced mdm-2-mediated ubiquitination and degradation of p53. J Biol Chem 277, 21843–50. 2002

    Article  PubMed  CAS  Google Scholar 

  • Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis proteininduces apotosis in chemoresistant human ovarian cancer cells. Cancer Res 60, 5659–66. 2000

    PubMed  CAS  Google Scholar 

  • Simsek T, Ozbilim G, Gulkesen H, Kaya H, Sargin F, Karaveli S. Drug resistance in epithelial ovarian cancer: P-Glycoprotein and Gluthadion S-transferase. Can they play an important role in detection response to platinum-based chemotherapy as a first-line therapy. Eur J Gynecol Oncol 22(6), 436–38. 2001

    CAS  Google Scholar 

  • Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genom Biol 2 (Reviews3009). 2001

    Google Scholar 

  • Yang YL, Li XM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 10, 169–77. 2000.

    Article  PubMed  CAS  Google Scholar 

  • Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ Akt2 inhibition in cisplatin-induced JNK/p38 and Bax activation by phosphorylation of Ask I: Implication of Akt2 in chemoresistance. J Biol Chem 278(26), 23432–23440. 2003

    Article  PubMed  CAS  Google Scholar 

Literatur

  • Alagoz T, Buller RE, Berman M et al. What is a normal CA 125 level? Gynecol Oncol 1994; 53 (1): 93

    Article  PubMed  CAS  Google Scholar 

  • Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7 (Suppl 5): 20–8

    Article  PubMed  CAS  Google Scholar 

  • Averette HE, Steren H, Nguyen HN. Screening in gynecologic cancers. Cancer 1993; 72: 1043

    Article  PubMed  CAS  Google Scholar 

  • Bast RC Jr, Feeney M, Lazarus H et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331–1337

    Article  PubMed  Google Scholar 

  • Bast RC Jr, Klug TL, St John E et al. Radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883–887

    PubMed  Google Scholar 

  • Bast RC Jr, Xu FJ, Yu YH et al. CA 125: the past and the future. Int J Biol Markers 1998; 13 (4): 179–87

    PubMed  CAS  Google Scholar 

  • Bell R, Petticrew M. Screening people with a family history of cancer. Benefit of screening for ovarian cancer is unproved. BMJ 1997; 15; 315(7118): 1306

    PubMed  CAS  Google Scholar 

  • Bell R, Petticrew M, Luengo S et al. Screening for ovarian cancer: a systematic review. Health Technol Assess 1998; 2 (2): i–iv, 1–84

    PubMed  CAS  Google Scholar 

  • Berkowitz RS. CA 125 measurement in epithelial ovarian cancer: A 10-year anniversary of clinical investigation. Gynecol Oncol 1993; 49: 1

    Article  PubMed  CAS  Google Scholar 

  • Bourne TH, Campbell S, Reynolds K et al. The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer. Gynecol Oncol 1994; 52 (3): 379

    Article  PubMed  CAS  Google Scholar 

  • Bridgewater JA, Nelstrop AE, Rustin GJS et al. Comparison of standard and CA-125 response criteria in patient with epithelial ovarian cancer treated with platinum or paclitaxel. J. Clin Oncol 1999; 17: 501–508

    PubMed  CAS  Google Scholar 

  • Buller RE, Berman ML, Bloss JD et al. Serum CA 125 regression in epithelial ovarian cancer: correlation with reassessment findings and survival. Gynecol Oncol 1992; 47 (1): 87

    Article  PubMed  CAS  Google Scholar 

  • Creasman WT, DiSaia PJ. Screening in ovarian cancer. Am J Obstet Gynecol 1991; 165: 7

    PubMed  CAS  Google Scholar 

  • D’Aloia A, Faggiano P, Aurigemma G et al. Serum level of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 2003; 41 (10): 1805–11

    Article  PubMed  CAS  Google Scholar 

  • Davelaar EM, Bonfer JMG, Verstraeten RA et al. Ca 125: a valid marker in ovarian carcinoma patients treated with paditaxel? Cancer 1996; 78 (1): 118–27

    Article  PubMed  CAS  Google Scholar 

  • Diamandis EP. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002; 360 (9327): 169–170

    Article  Google Scholar 

  • Dorum A, Kristensen GB, Abeler VM et al. Early detection of familial ovarian cancer. Eur J Cancer 1996; 32 (10): 1645

    Article  Google Scholar 

  • Duffy MJ, Bonfrer JM, Kulpa J et al. CA 125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15 (5): 679–91

    Article  PubMed  CAS  Google Scholar 

  • Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12: 2654–2666

    PubMed  CAS  Google Scholar 

  • Eisenhauer EA, Vermorken JB, Glabbeke M van. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997; 8: 963–968

    Article  PubMed  CAS  Google Scholar 

  • Elwood M. Proteomic patterns in serum and identification of ovarian cancer. Lancet 2002, 360 (9327): 170

    Article  PubMed  Google Scholar 

  • Fung MF, Bryson P, Johnston M et al. Screening postmenopausal women for ovarian cancer: a systematic review. J Obstet Gynaecol Can 2004; 26 (8): 717–28

    PubMed  Google Scholar 

  • Gaducci A, Ferdeghni M, Prontera C et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevence for differential diagnosis. Gynecol Oncol 1992; 44 (2): 147

    Article  Google Scholar 

  • Gaducci A, Zola P, Landoni F et al. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol 1995; 58 (1): 42

    Article  Google Scholar 

  • Gronlund B, Hansen HH, Hogdall C et al. Do CA 125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma? Br J Cancer 2004a; 90 (2): 377–82

    Article  PubMed  CAS  Google Scholar 

  • Gronlund B, Hogdall C, Hilden J et al. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemortherapy of ovarian carcinoma? J Clin Oncol 2004b; 22 (20): 4051–8

    Article  PubMed  Google Scholar 

  • Guastalla JP, Vincent P, Le Rol A et al. CA 125 evaluation of chemotherapy response in patients with recurrent ovarian cancer: Rustin criteria revisited. Proc Am Soc Clin Oncol 2002; 21: 204a

    Google Scholar 

  • Hawkins RE et al. The clinical correlates of serum CA 125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer 1989; 60 (4): 634

    PubMed  CAS  Google Scholar 

  • Hensley ML, Robson ME, Kauff ND et al. Pre-and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecol Oncol 2003; 89 (3): 440–6

    Article  PubMed  Google Scholar 

  • Herberman RB. Uses and limitations of tumor markers. In: Fishman WH (ed) Oncodevelopmental markers, biologic, diagnostic and monitoring aspects. Academic Press, New York 1983

    Google Scholar 

  • Hogberg T, Kagedal B. Serum half-life of the tumor marker CA 125 during induction chemotherapy as a prognostic indicator for survival in ovarian carcinoma. Acta Obstet Gynecol Scand 1990; 69: 423

    Article  PubMed  CAS  Google Scholar 

  • Jacobs I, Oram D, Fairbanks J et al. A risk of malignancy index incorporating CA 125, ultrasound and men opausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97 (10): 922

    PubMed  CAS  Google Scholar 

  • Jacobs I, Davies AP, Bridges J et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993; 306 (6884): 1030

    Article  PubMed  CAS  Google Scholar 

  • Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353 (9160): 1207–1210

    Article  PubMed  CAS  Google Scholar 

  • Jeyarajah AR, Ind TE, Skates S et al. Serum CA 125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer 1999; 85 (9): 2068–2072

    PubMed  CAS  Google Scholar 

  • Karlan BY, Baldwin RL, Lopez-Luevanos E et al. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am J Obstet Gynecol 1999; 180 (4): 917

    Article  PubMed  CAS  Google Scholar 

  • Kauff ND, Hurley KE, Hensley ML et al. Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. Cancer 2005; 104 (2): 314–20

    Article  PubMed  Google Scholar 

  • Kreienberg R. Allgemeine und spezifische Laborparameter im Rahmen der Tum ornachsorge bei gynäkologischen Malignomen und bei Mammakarzinomen. Gynäkologe 1989; 22: 55

    PubMed  CAS  Google Scholar 

  • Lambert HE, Rustin GJ, Gregory WM et al. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Ann Oncol 1997; 8: 327–333

    Article  PubMed  CAS  Google Scholar 

  • Lynch HT. Genetic risk in ovarian cancer. Gynecol Oncol 1992; 46: 1

    Article  PubMed  CAS  Google Scholar 

  • Makar AP, Kristensen GB, Kaern J et al. Prognostic value of pre-and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992; 79 (6): 1002

    PubMed  CAS  Google Scholar 

  • Makar AP, Kristensen GB, Bormer OP et al. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer? Gynecol Oncol 1993a; 49 (1): 3

    Article  PubMed  CAS  Google Scholar 

  • Makar AP, Kristensen GB, Bormer OP et al. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 1993b; 49 (1): 73

    Article  PubMed  CAS  Google Scholar 

  • Malkasian GD, Knapp RC, Lavin PT et al. Pre-operative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign and malign disease. Am J Obstet Gynecol 1988; 159: 341

    PubMed  Google Scholar 

  • Markman M. A proposal to use CA-125 to evaluate activity of new antineoplastic agents in ovarian cancer. Gynecol Oncol 1993; 51: 297–298

    Article  PubMed  CAS  Google Scholar 

  • Markman M, Kennedy A, Kim J. Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy. Gynecol Oncol 2001; 83 (3): 593–5

    Article  PubMed  CAS  Google Scholar 

  • Meeuwissen PA, Seynaeve C, Brekelmans CT et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 2005; 97 (2): 476–82

    Article  PubMed  Google Scholar 

  • Meier W, Stieber P, Fateh-Moghadam A et al. Prognostische Bedeutung der CA 125 Halbwertszeit für den weiteren Krankheitsverlauf beim Ovarialkarzinom. Geburtsh Frauenheilkd 1992; 52: 526

    Article  CAS  Google Scholar 

  • Meier W, Römisch M, Hepp H. Stellenwert der Rezidivchirurgie beim Ovarialkarzinom. Geburtsh Frauenheilkd 1993; 53: 30

    Article  CAS  Google Scholar 

  • Meier W, Baumgartner L, Stieber P et al. Significance of tumor marker determinations in the primary therapy of ovarian cancer. Anticancer Research 1997a; 17: 2949–2952

    PubMed  CAS  Google Scholar 

  • Meier W, Baumgartner L, Stieber P et al. CA 125 based diagnosis and therapy in recurrent ovarian cancer. Anticancer Research 1997b; 17: 3019–3020

    PubMed  CAS  Google Scholar 

  • Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44: 207

    Article  PubMed  CAS  Google Scholar 

  • Moss EL, Hollingworth J, Reynolds TM. The role of CA 125 in clinical practice. J Clin Pathol 2005; 58 (3): 308–12

    Article  PubMed  CAS  Google Scholar 

  • Nagele F, Petru E, Medl M et al. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995; 86 (2): 259

    Article  PubMed  CAS  Google Scholar 

  • Ng LW, Homesley HD, Barrett RJ et al. CA 125 values predictive of clinical response during second-line chemotherapy for epithelial ovarian cancer. Am J Clin Oncol 1989; 12: 106–109

    Article  PubMed  CAS  Google Scholar 

  • O’Brien TJ, Beard JB, Underwood LJ et al. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001; 22: 348–366

    Article  PubMed  Google Scholar 

  • Olivier RI, Lubsen-Brandsma MA, Verhoef S, Beurden M van. CA 125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 2006: 100 (1): 20–6

    Article  PubMed  CAS  Google Scholar 

  • Onsrud M. Tumour markers in gynaecologic oncology. Scand J Clin Lab Invest Suppl 1991; 206: 60

    Article  PubMed  CAS  Google Scholar 

  • Parker D, Bradley C, Bogle SM et al. Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer. Br J Obstet Gynaecol 1994; 101 (10): 888

    PubMed  CAS  Google Scholar 

  • Paulsen T, Marth C, Kaem J et al. Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients. Gynecol Oncol 2000; 76 (3): 326–30

    Article  PubMed  CAS  Google Scholar 

  • Pearl ML, Yashar CM, Johnstone CM et al. Exponential regression of CA 125 during salvage treatment for ovarian cancer with taxol. Gynecol Oncol 1994; 53: 339–343

    Article  PubMed  CAS  Google Scholar 

  • Petricoin EF III, Ardekani AA, Hitt BA et al. Uso of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359 (9306): 572–577

    Article  PubMed  CAS  Google Scholar 

  • Podczaski E, Whitney C, Manetta A et al. Uso of CA 125 to monitor patients with ovarian epithelial carcinomas. Gynecol Oncol 1990; 33: 193

    Article  Google Scholar 

  • Roman LD, Muderspach LI, Burnett AF et al. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility? J Reprod Med 1998; 43 (5): 403

    PubMed  CAS  Google Scholar 

  • Rosen A, Sevelda P, Klein M et al. A CA 125 score is a prognostic index in patients with ovarian cancer. Arch Gynecol Obstet 1990; 247 (3): 125

    Article  PubMed  CAS  Google Scholar 

  • Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21 (10 Suppl): 187–93

    Article  Google Scholar 

  • Rustin GJ, Nelstrop A, Stilwell J et al. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer 1992; 28: 79–82

    Article  PubMed  CAS  Google Scholar 

  • Rustin GJ, Burg ME van der, Berek JS. Advanced ovarian cancer. Tumor markers. Ann Oncol 1993; 4 (Suppl 4): 71–77

    PubMed  Google Scholar 

  • Rustin GJ, Nelstrop AE, Tuxen MK et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996a: 7: 361–364

    PubMed  CAS  Google Scholar 

  • Rustin GJ, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol 1996b; 14: 1545–1551

    PubMed  CAS  Google Scholar 

  • Rustin GJ, Nelstrop AE, Bentzen SM et al. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000; 18 (8): 1733–9

    PubMed  CAS  Google Scholar 

  • Rustin GJ, Marples M, Nelstrop AE et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001; 19: 4054–4057

    PubMed  CAS  Google Scholar 

  • Sjövall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and non-malignant diseases. Gynecol Oncol 2002; 85 (1): 175–178

    Article  PubMed  Google Scholar 

  • Skates SJ, Xu FJ, Yu YH et al. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 1995; 76 (10 Suppl): 2004

    Article  PubMed  CAS  Google Scholar 

  • Skates SJ, Chang Y, Xu FJ et al. A new statistical approach to screening for ovarian cancer. Tumor Biol 1996; 17: 45

    Google Scholar 

  • Skates SJ, Menon U, MacDonald N et al. Calculation of the risk for ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003; 21 (10 Suppl): 206–210

    Article  Google Scholar 

  • Skates SJ, Horik N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA72-4 and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004; 22 (20): 4059–66

    Article  PubMed  Google Scholar 

  • Smith LH, Morris CR, Yasmeen S et al. Ovarian cancer: can we make the clinical diagnosis earlier? Cancer 2005; 104 (7): 1398–407

    Article  PubMed  Google Scholar 

  • Sogaard CH, Lindegaard JC, Havsten H et al. Chemotherapy-induced changes of CA 125 in patients with epithelial ovarian cancer. Gynecol Oncol 2005; 97 (2): 410–2

    Article  PubMed  CAS  Google Scholar 

  • Stenman UH, Alfthan H, Vartiainen J et al. Markers supplementing CA 125 in ovarian cancer. Ann Med 1995; 27 (1): 115

    Article  PubMed  CAS  Google Scholar 

  • Stieber P, Fateh-Moghadam A. Tumormaker und ihr sinnvoller Einsatz. Der Bay Int 1990; 10: 70

    Google Scholar 

  • Talbot R. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynaecol Obstet 1989; 168: 407–412

    CAS  Google Scholar 

  • Tate S, Hirai Y, Takeshima N, Hasumi K. CA 125 regression during neo-adjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol 2005; 96 (1): 143–9

    Article  PubMed  CAS  Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Nall Cancer Inst 2000; 92: 205–216

    Article  CAS  Google Scholar 

  • Tingulstad S, Hagen B, Skjeldestad FE et al. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999; 93 (3): 448–452

    Article  PubMed  CAS  Google Scholar 

  • Tuxen MK, Soletormos G, Combernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br J Cancer 2001; 84 (10): 1301–7

    Article  PubMed  CAS  Google Scholar 

  • Van der Burg ME, Lammers FB, Putten WJL van, Stoler G. Ovarian cancer: the prognostic value of the serum half-life of CA 125 during induction chemotherapy. Gynecol Oncol 1988; 30 (3): 307

    Article  PubMed  Google Scholar 

  • Van der Burg ME, Lammers FB, Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol 1990; 1: 301–302

    PubMed  Google Scholar 

  • Vergote I, Rustin GJS, Eisenhauer ET et al. New guidenlines to evaluate the response to treatment in solid rumors (ovarian cancer). J Natl Cancer Inst 2000; 92: 1534–1535

    Article  PubMed  CAS  Google Scholar 

  • Yin BW, Lloyd KO. Molecular cloning of the CA 125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276: 27371–27375

    Article  PubMed  CAS  Google Scholar 

  • Zurawski VR Jr, Orjaseter H, Andersen A et al. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer. Int J Cancer 1988a; 42 (5): 677–680

    Article  PubMed  Google Scholar 

  • Zurawski VR, Knapp RC, Einhorn N et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol 1988b; 30: 7

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsfrauenklinik, Prittwitzstraße 43, 89075, Ulm

    Prof. Dr. med. R. Kreienberg

  2. Universitäts-Frauenklinik, Hugstetterstraße 55, 79106, Freiburg

    Prof. Dr. med. H. J. Prömpeler

  3. Krankenhaus Neuperlach, Institut für Röntgendiagnostik und Nukleamedizin, Oskar-Maria-Gaf-Ring 51, 81737, München

    Prof. Dr. med. A. Rieber-Brambs

  4. Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Universitätsklinikum Gießen und Marburg GmbH, Baldingerstraße 1, 35043, Marburg

    Dr. med. K. H. Baumann & Prof. Dr. med. U. Wagner

  5. Gynäkologisch-Onkologische Praxis am Pelikanplatz, Pelikanplatz 23, 30177, Hannover

    Prof. Dr. med. H. -J. Lück

  6. Gynäkologie und Geburtshilfe, Evangelisches Krankenhaus, Kirchfeldstr. 40, 40217, Düsseldorf

    Prof. Dr. med. W. Meier

  7. Gynäkologie und Geburtshilfe, Malteser Krankenhaus Bonn/Rhein-Sieg, Von-Hompesch-Straße 1, 53123, Bonn

    Dr. med. M. Gropp

Authors
  1. Prof. Dr. med. R. Kreienberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. H. J. Prömpeler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. A. Rieber-Brambs
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dr. med. K. H. Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Prof. Dr. med. U. Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Prof. Dr. med. H. -J. Lück
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Prof. Dr. med. W. Meier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dr. med. M. Gropp
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Kreienberg, R. et al. (2009). Diagnostik. In: Management des Ovarialkarzinoms. Onkologie aktuell. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68857-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68857-0_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41987-7

  • Online ISBN: 978-3-540-68857-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation